SEC Contract Filing

Filing Date: 2015-11-06

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a20150930-ex102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
 <!-- Document created using Wdesk 1 -->
 <!-- Copyright 2015 Workiva -->
 <title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s02099413CBA44CF79A619FC4CBC491B7"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14.5pt;"><font style="font-family:inherit;font-size:14.5pt;"><br></font></div><div style="line-height:282%;padding-top:2px;text-align:right;font-size:26.5pt;"><img src="missionpharmacallette_image1.gif" style="height:40px;width:44px;"><font style="font-family:inherit;font-size:26.5pt;font-weight:bold;">Mission&#174;</font></div><div style="line-height:142%;text-align:right;font-size:14.5pt;"><font style="font-family:inherit;font-size:14.5pt;">PHARMACAL</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:right;text-indent:576px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.2</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">October 15, 2015</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">&#32;Stephen Aselage</font></div><div style="line-height:128%;text-align:left;padding-left:8px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">CEO</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">Retrophin Inc.</font></div><div style="line-height:128%;padding-top:1px;text-align:left;padding-left:6px;text-indent:1px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">12255 El Camino Real, Suite 250 San Diego, CA 92130</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:257%;text-align:left;padding-left:8px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">Re: Addendum to Trademark License and Supply Agreement dated May 28, 2014 Dear Stephen,</font></div><div style="line-height:128%;text-align:justify;padding-left:6px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">As you are aware, Retrophin has requested that Mission Pharmacal build a significant safety stock of tiopronin, the active pharmaceutical ingredient (API) in THIOLA. The safety stock is requested to insure that there is no interruption in the supply of THIOLA and to prepare for a potential development project, whereby THIOLA may be reformulated. Due to the financial burden of purchasing such large quantities of tiopronin prior to firm production orders, Mission is requesting immediate reimbursement for the safety stock purchases.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:128%;text-align:justify;padding-left:8px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">In order for Mission to execute on the acquisition of safety stock, Retrophin will need to submit an agreed upon annual plan of API purchases. Mission will then work with the approved supplier to schedule production and purchases. The Annual Plan of API purchases is attached to this letter agreement and agreed upon by the parties.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:128%;text-align:justify;padding-left:6px;text-indent:1px;font-size:11.5pt;"><font style="font-family:inherit;font-size:10.5pt;">On Retrophin'</font><font style="font-family:inherit;font-size:11.5pt;font-style:italic;">s </font><font style="font-family:inherit;font-size:10.5pt;">behalf, Mission will purchase the agreed quantities of tiopronin safety stock. Mission requests that Retrophin issue a detailed demand forecast, outlining the quantities required for safety stock. Mission will then work with the supplier to order the requested API. Mission will prepare a purchase order detailing the amount of API to be ordered, the purchase price, and the total amount due to the supplier. Mission will then submit the purchase order and a detailed invoice to Retrophin for approval. The sum of the Mission invoice will be the total amount due from the prepared purchase order pl us a 5% administration fee due to Mission. Following Retrophin's review and approval of the submitted purchase order and invoice, Retrophin will submit full payment for the invoice via wire transfer to Mission. Following receipt of Retrophin's approval and payment, Mission will issue a p